• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:54:16 AM ET
    $BBI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BBI alert in real time by email
    SC 13G/A 1 tm216476d25_sc13ga.htm SC 13G/A

     

     

    CUSIP No: 10802T105

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Brickell Biotech, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    10802T105

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

    xRule 13d-1(c)

    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 10802T105

     

    (1) NAMES OF REPORTING PERSONS
     
        CVI Investments, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Cayman Islands
         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

    (5) SOLE VOTING POWER
    0  
       
    (6) SHARED VOTING POWER **
       
    2,810,675
     
     
    (7) SOLE DISPOSITIVE POWER
       
    0  
       
       
    (8) SHARED DISPOSITIVE POWER **
       
    2,810,675
       
       
      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    2,810,675

       
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 10802T105

     

    (1) NAMES OF REPORTING PERSONS
     
        Heights Capital Management, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Delaware
         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

    (5) SOLE VOTING POWER
    0  
       
    (6) SHARED VOTING POWER **
       
    2,810,675
     
     
    (7) SOLE DISPOSITIVE POWER
       
    0  
       
       
    (8) SHARED DISPOSITIVE POWER **
       
    2,810,675
       
      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    2,810,675

       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 10802T105

     

    Item 1.

     

    (a)Name of Issuer

     

    Brickell Biotech, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    5777 Central Avenue, Suite 102, Boulder, CO 80301

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.01 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)  Title of Class of Securities

     

    Common stock, $0.01 par value per share

     

    Item 2(e)  CUSIP Number

     

    10802T105

     

     

     

     

    CUSIP No: 10802T105

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
        
    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
        
    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
        
    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
        
    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
        
    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
        
    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
        
    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940(15 U.S.C. 80a-3);
        
    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
        
    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 53,515,476 Shares outstanding as of November 5, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 10802T105

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 10802T105

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.

    HEIGHTS CAPITAL MANAGEMENT, INC.

     

    By: Heights Capital Management, Inc.   

    By:

    /s/ Brian Sopinsky

    pursuant to a Limited Power of

    Name:

    Brian Sopinsky
    Attorney, a copy of which was Title: Secretary
    previously filed    

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     
     

     

    CUSIP No: 10802T105

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

     

    Get the next $BBI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBI

    DatePrice TargetRatingAnalyst
    3/8/2022Outperform
    William Blair
    1/18/2022$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BBI
    Financials

    Live finance-specific insights

    See more
    • Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second qua

      8/11/22 4:05:00 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

      BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights. To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conferenc

      8/2/22 4:05:00 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales Sale reflects Brickell's new business strategy and commitment to developing its pipeline of novel, potential first-in-class treatments in immunology and inflammation On track to initiate a Phase 1 study of BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases, in the second quarter of 2022, with SAD and MAD topline results expected by early 2023 BOULDER, Colo., May 12, 2022 (GLOBE

      5/12/22 4:01:00 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Brickell Biotech Inc.

      10-Q - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      11/10/22 7:19:43 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      11/10/22 4:10:26 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      9/20/22 4:48:21 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Floor & Decor Holdings, Inc. (NYSE: FND)

      NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Believes That Floor & Decor's Ballooning Capital Expenditures and New Store Operating Costs in Lower Income and New Geographic Markets Will Severely Impair its Earnings Potential Identifies at Least Ten Other Areas of Misperception That Suggest Floor & Decor's Challenges Are Structural and Are Not Cyclical or Easily Fixed Provides Evidence That Floor & Decor Recently Made Revisions to Key Revenue Claims, Numerous Omissions of Past Disclosures, Changes to Accounting Policy Language and Modifications to Business Practices That Obscure its Growing Challenges Provides Evidence That CEO Thom

      7/1/24 9:00:00 AM ET
      $CRI
      $FND
      $LIN
      $BBI
      Apparel
      Consumer Discretionary
      RETAIL: Building Materials
      Major Chemicals
    • Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

      FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it has initiated the multiple ascending dose ("MAD") portion of the ongoing Phase 1 clinical trial

      9/13/22 8:00:00 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

      New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol "FRTX" on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX's novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI) today announced that it has changed its name to Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company"). The new name, logo, website, and brand

      9/7/22 8:00:00 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Leadership Updates

    Live Leadership Updates

    See more
    • Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

      BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it has appointed Monica Luchi, MD, FACR, MBA to the newly created role of Chief Medical Officer. In this new role, Dr. Luchi will oversee the Company's clinical development strategy and medical affairs functions. "We are delighted to have Dr. Luchi join our team at this transformative point in our Company's history. Her tremendou

      9/1/21 7:05:00 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Brickell Biotech Inc. (Amendment)

      SC 13G/A - Brickell Biotech, Inc. (0000819050) (Subject)

      2/3/22 3:37:26 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Brickell Biotech, Inc. (Amendment)

      SC 13G/A - Brickell Biotech, Inc. (0000819050) (Subject)

      11/3/21 12:45:26 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brickell Biotech, Inc.

      SC 13G - Brickell Biotech, Inc. (0000819050) (Subject)

      7/22/21 8:59:28 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hardy Reginald L

      4 - Brickell Biotech, Inc. (0000819050) (Issuer)

      5/17/22 5:18:21 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Samant Vijay B

      4 - Brickell Biotech, Inc. (0000819050) (Issuer)

      5/17/22 5:16:32 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Lyons Gary A

      4 - Brickell Biotech, Inc. (0000819050) (Issuer)

      5/17/22 5:15:05 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Brickell Biotech

      William Blair initiated coverage of Brickell Biotech with a rating of Outperform

      3/8/22 6:55:45 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Brickell Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Brickell Biotech with a rating of Buy and set a new price target of $2.00

      1/18/22 6:11:49 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care